Loratadine and cetirizine in the treatment of chronic urticaria

L. Guerra, C. Vincenzi, E. Marchesi, Antonella Tosti, E. Pretto, R. Bassi, P. Ruetta Fabbian, F. De Costanza

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Aim This study was designed to compare loratadine and cetirizine in controlling the symptoms of chronic urticaria. Subjects One hundred and sixteen adult patients with chronic urticaria. Methods In this double-blind study the patients were randomly divided into three therapeutic groups: 38 received loratadine (10 mg), 40 cetirizine (10 mg) and 38 placebo tablets once daily for 28 days. Steroid-dependent subjects and patients with physical urticaria or with angioneurotic hereditary oedema as well as pregnant or breast-feeding women were excluded from the study. A suitable wash-out period was observed in case of previous treatments for the same disease. Itching, erythema, number of lesions and diameter of the largest one were evaluated according to a scale from 0 (absent) to 3 (severe). The minimum entry study score for itching plus number of lesions had to be at least equal to three. Control visits were scheduled after 3, 7 and 14 days of therapy. Symptoms, disease status, therapeutic response, side effects and compliance were evaluated at each visit. Diary cards were filled in by patients at home. Results Active drugs compared to placebo significantly reduced global clinical symptoms (P < 0.05). Loratadine was more rapid in developing its activity than the other two agents (P < 0.01 at day 3). Each single symptom showed the same trend. At the end of the study 24 (63%) patients treated with loratadine, 18 (45%) with cetirizine and 5 (13%) with placebo were free from symptoms. Four failures occurred with loratadine, six with cetirizine and seventeen with placebo. The tolerability profile was similar for all three groups. One patient receiving cetirizine dropped out due to severe gastric pain. Conclusions Loratadine is more active and safer than cetirizine in the treatment of chronic urticaria.

Original languageEnglish
Pages (from-to)148-152
Number of pages5
JournalJournal of the European Academy of Dermatology and Venereology
Volume3
Issue number2
StatePublished - Mar 1 1994
Externally publishedYes

Fingerprint

Loratadine
Cetirizine
Urticaria
Placebos
Pruritus
Therapeutics
Hereditary Angioedemas
Erythema
Breast Feeding
Double-Blind Method
Tablets
Compliance
Stomach
Steroids
Pain
Pharmaceutical Preparations

Keywords

  • Cetirizine
  • Chronic urticaria
  • Loratadine
  • Onset of action
  • Tachyphylaxis

ASJC Scopus subject areas

  • Infectious Diseases
  • Dermatology

Cite this

Guerra, L., Vincenzi, C., Marchesi, E., Tosti, A., Pretto, E., Bassi, R., ... De Costanza, F. (1994). Loratadine and cetirizine in the treatment of chronic urticaria. Journal of the European Academy of Dermatology and Venereology, 3(2), 148-152.

Loratadine and cetirizine in the treatment of chronic urticaria. / Guerra, L.; Vincenzi, C.; Marchesi, E.; Tosti, Antonella; Pretto, E.; Bassi, R.; Ruetta Fabbian, P.; De Costanza, F.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 3, No. 2, 01.03.1994, p. 148-152.

Research output: Contribution to journalArticle

Guerra, L, Vincenzi, C, Marchesi, E, Tosti, A, Pretto, E, Bassi, R, Ruetta Fabbian, P & De Costanza, F 1994, 'Loratadine and cetirizine in the treatment of chronic urticaria', Journal of the European Academy of Dermatology and Venereology, vol. 3, no. 2, pp. 148-152.
Guerra, L. ; Vincenzi, C. ; Marchesi, E. ; Tosti, Antonella ; Pretto, E. ; Bassi, R. ; Ruetta Fabbian, P. ; De Costanza, F. / Loratadine and cetirizine in the treatment of chronic urticaria. In: Journal of the European Academy of Dermatology and Venereology. 1994 ; Vol. 3, No. 2. pp. 148-152.
@article{aa5148bf30d1493fbe9e9682b64e3b03,
title = "Loratadine and cetirizine in the treatment of chronic urticaria",
abstract = "Aim This study was designed to compare loratadine and cetirizine in controlling the symptoms of chronic urticaria. Subjects One hundred and sixteen adult patients with chronic urticaria. Methods In this double-blind study the patients were randomly divided into three therapeutic groups: 38 received loratadine (10 mg), 40 cetirizine (10 mg) and 38 placebo tablets once daily for 28 days. Steroid-dependent subjects and patients with physical urticaria or with angioneurotic hereditary oedema as well as pregnant or breast-feeding women were excluded from the study. A suitable wash-out period was observed in case of previous treatments for the same disease. Itching, erythema, number of lesions and diameter of the largest one were evaluated according to a scale from 0 (absent) to 3 (severe). The minimum entry study score for itching plus number of lesions had to be at least equal to three. Control visits were scheduled after 3, 7 and 14 days of therapy. Symptoms, disease status, therapeutic response, side effects and compliance were evaluated at each visit. Diary cards were filled in by patients at home. Results Active drugs compared to placebo significantly reduced global clinical symptoms (P < 0.05). Loratadine was more rapid in developing its activity than the other two agents (P < 0.01 at day 3). Each single symptom showed the same trend. At the end of the study 24 (63{\%}) patients treated with loratadine, 18 (45{\%}) with cetirizine and 5 (13{\%}) with placebo were free from symptoms. Four failures occurred with loratadine, six with cetirizine and seventeen with placebo. The tolerability profile was similar for all three groups. One patient receiving cetirizine dropped out due to severe gastric pain. Conclusions Loratadine is more active and safer than cetirizine in the treatment of chronic urticaria.",
keywords = "Cetirizine, Chronic urticaria, Loratadine, Onset of action, Tachyphylaxis",
author = "L. Guerra and C. Vincenzi and E. Marchesi and Antonella Tosti and E. Pretto and R. Bassi and {Ruetta Fabbian}, P. and {De Costanza}, F.",
year = "1994",
month = "3",
day = "1",
language = "English",
volume = "3",
pages = "148--152",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Loratadine and cetirizine in the treatment of chronic urticaria

AU - Guerra, L.

AU - Vincenzi, C.

AU - Marchesi, E.

AU - Tosti, Antonella

AU - Pretto, E.

AU - Bassi, R.

AU - Ruetta Fabbian, P.

AU - De Costanza, F.

PY - 1994/3/1

Y1 - 1994/3/1

N2 - Aim This study was designed to compare loratadine and cetirizine in controlling the symptoms of chronic urticaria. Subjects One hundred and sixteen adult patients with chronic urticaria. Methods In this double-blind study the patients were randomly divided into three therapeutic groups: 38 received loratadine (10 mg), 40 cetirizine (10 mg) and 38 placebo tablets once daily for 28 days. Steroid-dependent subjects and patients with physical urticaria or with angioneurotic hereditary oedema as well as pregnant or breast-feeding women were excluded from the study. A suitable wash-out period was observed in case of previous treatments for the same disease. Itching, erythema, number of lesions and diameter of the largest one were evaluated according to a scale from 0 (absent) to 3 (severe). The minimum entry study score for itching plus number of lesions had to be at least equal to three. Control visits were scheduled after 3, 7 and 14 days of therapy. Symptoms, disease status, therapeutic response, side effects and compliance were evaluated at each visit. Diary cards were filled in by patients at home. Results Active drugs compared to placebo significantly reduced global clinical symptoms (P < 0.05). Loratadine was more rapid in developing its activity than the other two agents (P < 0.01 at day 3). Each single symptom showed the same trend. At the end of the study 24 (63%) patients treated with loratadine, 18 (45%) with cetirizine and 5 (13%) with placebo were free from symptoms. Four failures occurred with loratadine, six with cetirizine and seventeen with placebo. The tolerability profile was similar for all three groups. One patient receiving cetirizine dropped out due to severe gastric pain. Conclusions Loratadine is more active and safer than cetirizine in the treatment of chronic urticaria.

AB - Aim This study was designed to compare loratadine and cetirizine in controlling the symptoms of chronic urticaria. Subjects One hundred and sixteen adult patients with chronic urticaria. Methods In this double-blind study the patients were randomly divided into three therapeutic groups: 38 received loratadine (10 mg), 40 cetirizine (10 mg) and 38 placebo tablets once daily for 28 days. Steroid-dependent subjects and patients with physical urticaria or with angioneurotic hereditary oedema as well as pregnant or breast-feeding women were excluded from the study. A suitable wash-out period was observed in case of previous treatments for the same disease. Itching, erythema, number of lesions and diameter of the largest one were evaluated according to a scale from 0 (absent) to 3 (severe). The minimum entry study score for itching plus number of lesions had to be at least equal to three. Control visits were scheduled after 3, 7 and 14 days of therapy. Symptoms, disease status, therapeutic response, side effects and compliance were evaluated at each visit. Diary cards were filled in by patients at home. Results Active drugs compared to placebo significantly reduced global clinical symptoms (P < 0.05). Loratadine was more rapid in developing its activity than the other two agents (P < 0.01 at day 3). Each single symptom showed the same trend. At the end of the study 24 (63%) patients treated with loratadine, 18 (45%) with cetirizine and 5 (13%) with placebo were free from symptoms. Four failures occurred with loratadine, six with cetirizine and seventeen with placebo. The tolerability profile was similar for all three groups. One patient receiving cetirizine dropped out due to severe gastric pain. Conclusions Loratadine is more active and safer than cetirizine in the treatment of chronic urticaria.

KW - Cetirizine

KW - Chronic urticaria

KW - Loratadine

KW - Onset of action

KW - Tachyphylaxis

UR - http://www.scopus.com/inward/record.url?scp=0028269553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028269553&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028269553

VL - 3

SP - 148

EP - 152

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 2

ER -